Analysts See $-0.31 EPS for Catabasis Pharmaceuticals, Inc. (CATB)

February 23, 2018 - By Marie Mckinney

 Analysts See $ 0.31 EPS for Catabasis Pharmaceuticals, Inc. (CATB)

Analysts expect Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) to report $-0.31 EPS on March, 15.They anticipate $0.16 EPS change or 34.04 % from last quarter’s $-0.47 EPS. After having $-0.31 EPS previously, Catabasis Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. The stock increased 8.77% or $0.135 during the last trading session, reaching $1.675. About 1.36M shares traded or 63.76% up from the average. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has declined 73.74% since February 23, 2017 and is downtrending. It has underperformed by 90.44% the S&P500.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Ratings Coverage

Among 5 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Catabasis Pharmaceuticals had 14 analyst reports since August 17, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Thursday, October 5 by Citigroup. The stock of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) earned “Buy” rating by Citigroup on Thursday, June 9. On Thursday, October 5 the stock rating was maintained by Cowen & Co with “Hold”. H.C. Wainwright initiated Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) on Thursday, December 22 with “Buy” rating. The stock has “Outperform” rating by Wedbush on Wednesday, June 8. Citigroup upgraded the shares of CATB in report on Monday, November 20 to “Buy” rating. Oppenheimer maintained Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) rating on Monday, August 14. Oppenheimer has “Buy” rating and $400 target. Cowen & Co maintained Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) rating on Thursday, August 10. Cowen & Co has “Hold” rating and $200 target. On Tuesday, March 22 the stock rating was maintained by Citigroup with “Buy”. The rating was maintained by Wedbush with “Buy” on Monday, August 17.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company has market cap of $38.66 million. The firm offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It currently has negative earnings. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

Another recent and important Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) news was published by which published an article titled: “Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and …” on February 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.